Decipher Labs

Why is Decipher Labs Ltd falling/rising?

As of 18-Jul, Decipher Labs Ltd's stock price is at 6.29, reflecting a 4.7% decrease and significant underperformance with a 10.14% loss over the last three days. The stock is trading below all key moving averages, indicating a persistent downward trend, compounded by weak financial results and declining investor interest.

As of 18-Jul, Decipher Labs Ltd's stock price is falling, currently at 6.29, which reflects a decrease of 0.31 or 4.7%. The stock has been underperforming significantly, having lost 10.14% over the last three days and has consistently declined for three consecutive days. This trend is further supported by the fact that the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a persistent downward trajectory.<BR><BR>Investor participation has also diminished, with delivery volume dropping by 73.56% compared to the 5-day average, suggesting a lack of interest among investors. Additionally, the stock has shown weak long-term fundamental strength, evidenced by a staggering -208.36% compound annual growth rate (CAGR) in operating profits over the last five years and a negative EBITDA of Rs. -3.4 crore. The company has reported negative results for the last seven consecutive quarters, with net sales and profit after tax both declining by 26.77% in the latest six months.<BR><BR>Overall, the combination of poor financial performance, declining investor interest, and consistent underperformance against benchmarks has contributed to the stock's falling price.

Which are the latest news on Decipher Labs?

How big is Decipher Labs?

As of 10th June, Decipher Labs Ltd has a market capitalization of 7.00 Cr and reported net sales of 14.04 Cr with a loss of 4.31 Cr over the latest four quarters. Shareholder's Funds were 22.86 Cr and Total Assets were 23.89 Cr as of March 2025.

As of 10th June, Decipher Labs Ltd has a market capitalization of 7.00 Cr, classifying it as a Micro Cap company.<BR><BR>In the latest four quarters, Decipher Labs reported net sales of 14.04 Cr. However, the company experienced a loss of 4.31 Cr during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds amounted to 22.86 Cr and Total Assets were reported at 23.89 Cr.

Who are in the management team of Decipher Labs?

The management team of Decipher Labs consists of Sushant Mohan Lal (Executive Director), G Venkateswara Rao (Independent Director), and Megha Agarwal (Company Secretary & Compliance Officer).

The management team of Decipher Labs includes the following individuals:<BR><BR>1. Sushant Mohan Lal - Executive Director<BR>2. G Venkateswara Rao - Independent Director<BR>3. Megha Agarwal - Company Secretary & Compliance Officer<BR><BR>If you have any more questions about the company or its operations, feel free to ask!

Who are the peers of the Decipher Labs?

Decipher Labs' peers include Beryl Drugs, Unjha Formulations, Vivanza Biosciences, Ganga Pharma, Brawn Biotech, Shyama Computro, Fabino Enterprises, and Saroja Pharma. Most peers exhibit below-average management risk and growth, with Decipher Labs showing a 1-year return of -38.05%.

Peers: The peers of Decipher Labs are Beryl Drugs, Unjha Formul., Vivanza Biosci., Ganga Pharma., Brawn Biotech, Shyama Computro., Fabino Enter, and Saroja Pharma In.<BR><BR>Quality Snapshot: Below Average management risk is observed at Beryl Drugs, Vivanza Biosci., Ganga Pharma, Decipher Labs, Brawn Biotech, and Fabino Enter, while Average management risk is found at Unjha Formul. and Saroja Pharma In. Below Average growth is noted for Beryl Drugs, Unjha Formul., Vivanza Biosci., Ganga Pharma, Decipher Labs, Brawn Biotech, and Fabino Enter, while Average growth is seen at Vivanza Biosci. and Saroja Pharma In. Below Average capital structure is present at Beryl Drugs, Vivanza Biosci., Ganga Pharma, Decipher Labs, Brawn Biotech, and Fabino Enter, while Good capital structure is noted at Unjha Formul. and Average at Saroja Pharma In.<BR><BR>Return Snapshot: Beryl Drugs has the highest 1-year return at 31.73%, while Vivanza Biosci. has the lowest at -29.75%, with Decipher Labs showing a 1-year return of -38.05%. Additionally, Brawn Biotech, Vivanza Biosci., and Decipher Labs have negative six-month returns.

What does Decipher Labs do?

Decipher Labs Ltd, a Micro Cap company in the Pharmaceuticals & Biotechnology industry, was formerly known as Combat Drugs Limited and reported net sales of 4 Cr and a net profit of 0 Cr for the quarter ending March 2026. The company has a market cap of INR 7 Cr and operates from Hyderabad, Telangana.

Overview:<BR>Decipher Labs Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Decipher Labs Ltd was initially incorporated as Combat Drugs Private Limited in September 1986. It transitioned to a Public Limited Company and changed its name to Combat Drugs Limited in June 1992. The company was renamed Decipher Labs Limited on February 12, 2020. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 4 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 7 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.01 <BR>Return on Equity: -20.85% <BR>Price to Book: 0.34<BR><BR>Contact Details:<BR>Address: 4th Flr Plot-94 Sagar Society, Banjara Hills Road No 2 Hyderabad Telangana : 500034 <BR>Email: info@combatdrugs.in <BR>Website: http://www.combatdrugs.in

Are Decipher Labs Ltd latest results good or bad?

Decipher Labs Ltd's latest results are concerning, showing a net loss of ₹0.36 crores in Q4 FY26, a 33.33% increase in losses from the previous quarter, despite a slight revenue increase. The company continues to struggle with profitability and operational efficiency, raising doubts about its long-term viability.

Decipher Labs Ltd's latest results present a mixed picture, leaning more towards negative than positive. In Q4 FY26, the company reported a net loss of ₹0.36 crores, which is a 33.33% increase in losses compared to the previous quarter. While there was a slight improvement in revenue, with net sales rising to ₹3.60 crores (a 12.15% increase QoQ and 2.86% YoY), this growth is considered minimal for a pharmaceutical firm.<BR><BR>The operating margin did show some recovery, reaching 6.11% compared to -13.08% in Q3 FY26, indicating a marginal operational improvement. However, the profit after tax (PAT) margin remains deeply negative at -10.00%, although it improved from -16.82% in the previous quarter.<BR><BR>Overall, the company's financial performance reveals ongoing struggles with profitability and operational efficiency. The persistent net losses, combined with a significant decline in revenue over the past fiscal year, raise concerns about its long-term viability. Additionally, the stock has significantly underperformed compared to the broader market, reflecting investor skepticism about its recovery prospects. Thus, the latest results can be characterized as concerning, with multiple red flags indicating that the company is still facing substantial challenges.

Should I buy, sell or hold Decipher Labs Ltd?

When is the next results date for Decipher Labs Ltd?

The next results date for Decipher Labs Ltd is 30 May 2026.

The next results date for Decipher Labs Ltd is scheduled for 30 May 2026.

How has been the historical performance of Decipher Labs?

Decipher Labs has experienced a significant decline in net sales and profitability from March 2022 to March 2025, with net sales dropping from 65.32 Cr to 22.61 Cr and operating profit turning negative, resulting in a loss of 5.08 Cr after tax. Total assets and liabilities also decreased during this period, alongside a negative cash flow from operating activities.

Answer:<BR>The historical performance of Decipher Labs shows a significant decline in net sales and profitability over the years, particularly from March 2022 to March 2025.<BR><BR>Breakdown:<BR>Decipher Labs experienced a decrease in net sales from 65.32 Cr in March 2022 to 22.61 Cr in March 2025. This downward trend is reflected in total operating income, which also fell from 65.32 Cr in March 2022 to 22.61 Cr in March 2025. The company's total expenditure, excluding depreciation, peaked at 59.29 Cr in March 2022 but decreased to 29.84 Cr by March 2025. Operating profit (PBDIT) turned negative, going from a profit of 6.03 Cr in March 2022 to a loss of 7.23 Cr in March 2025. Consequently, profit after tax also declined sharply, from 11.38 Cr in March 2022 to a loss of 5.08 Cr in March 2025. The company's total assets decreased from 41.95 Cr in March 2022 to 23.89 Cr in March 2025, while total liabilities also fell from 41.95 Cr to 23.89 Cr in the same period. Cash flow from operating activities showed a negative trend, with a cash outflow of 9.00 Cr in March 2025, compared to a positive inflow of 8.00 Cr in March 2022. Overall, Decipher Labs has faced significant challenges in maintaining sales and profitability over the years.

Is Decipher Labs overvalued or undervalued?

As of June 2, 2025, Decipher Labs is considered overvalued with a risky valuation grade, reflected by a negative PE ratio of -2.22, an EV to EBITDA of -1.20, and a year-to-date stock return of -24.62%, significantly underperforming its peers and the Sensex.

As of 2 June 2025, Decipher Labs has moved from an attractive to a risky valuation grade. The company is currently considered overvalued based on its financial metrics, with a PE ratio of -2.22, an EV to EBITDA of -1.20, and a ROCE of -38.00%. These figures indicate significant financial distress and lack of profitability, which is further underscored by a negative PEG ratio of 0.00.<BR><BR>In comparison to its peers, Decipher Labs stands out negatively; for instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla shows a PE ratio of 22.99 and an EV to EBITDA of 15.93. The stark contrast in these ratios highlights Decipher Labs' struggles within the pharmaceuticals and biotechnology sector. Additionally, the company's stock has underperformed significantly against the Sensex, with a year-to-date return of -24.62% compared to the Sensex's 5.66%, reinforcing the notion that Decipher Labs is overvalued at its current price of 11.27.

What is the technical trend for Decipher Labs?

As of June 4, 2025, Decipher Labs is in a bearish trend with moderate strength, driven by bearish daily moving averages and Bollinger Bands, despite some mildly bullish MACD signals.

As of 4 June 2025, the technical trend for Decipher Labs has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include the daily moving averages, which are bearish, and the weekly and monthly Bollinger Bands also indicating a bearish trend. Although the MACD shows mildly bullish signals on both weekly and monthly time frames, the overall sentiment is dampened by the bearish moving averages and the Dow Theory, which is mildly bearish on both weekly and monthly scales. The stock's performance has significantly lagged behind the Sensex over various time frames, further supporting the bearish outlook.

Who are the top shareholders of the Decipher Labs?

The top shareholders of Decipher Labs include Ajjarapu Janakiram with 16.43% and Seshu Srinivas Akula with 3.8%. Individual investors collectively own 80.75% of the shares, with no institutional or pledged promoter holdings reported.

The top shareholders of Decipher Labs include Ajjarapu Janakiram, who holds the largest stake at 16.43%. The highest public shareholder is Seshu Srinivas Akula, with a holding of 3.8%. Additionally, individual investors collectively own a significant portion of the company, accounting for 80.75% of the shares. There are no institutional holdings or pledged promoter holdings reported.

Has Decipher Labs declared dividend?

No Dividend History Available